Nan Hu1, Hongyan Ji2. 1. Department of Neurology, Chinese Academy of Medical Sciences, Peking Union Medical College Hospital, Beijing, 100730, China. hunan_pumch@163.com. 2. Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, Hubei, China.
Abstract
OBJECTIVE: To investigate the association between the use of common medications on hypertension, hyperlipidemia, diabetes, and the risk of amyotrophic lateral sclerosis (ALS). METHODS: PubMed, EMBASE, OVID, and Web of Science were searched systematically until December 2021 for studies quantitatively investigating the effect of medications on hypertension, hyperlipidemia, and diabetes on the risk of ALS. We conducted a fixed-effects model or random-effects meta-analysis to calculate the summary ORs (odds ratios) and 95%CIs (confidence intervals). RESULTS: Regular intake of angiotensin-converting enzyme inhibitors (ACEIs) (OR: 0.81, 95%CI: 0.74, 0.89), beta-blockers (OR: 0.82, 95%CI: 0.76, 0.90), calcium-channel blockers (CCBs) (OR: 0.85, 95%CI: 0.79, 0.93), or diuretics (OR: 0.87, 95%CI: 0.81, 0.93) was inversely associated with the incidence of ALS. There was no significant association between statin use and risk of ALS (OR: 0.92, 95%CI: 0.83, 1.03). Metformin (OR: 0.83, 95%CI: 0.75, 0.93) and sulfonylureas (OR: 0.79, 95%CI:0.71, 0.89) use could significantly reduce the risk of ALS. CONCLUSION: Regular use of anti-hypertensive drugs and anti-diabetes including ACEIs, beta-blockers, CCBs, diuretics, metformin, and sulfonylureas could protect against the incidence of ALS. No significant association between anti-hyperlipidemia drug use and risk of ALS was revealed. Regular medications for hypertension, hyperlipidemia, and diabetes should be recommended regardless of the diagnosis of ALS.
OBJECTIVE: To investigate the association between the use of common medications on hypertension, hyperlipidemia, diabetes, and the risk of amyotrophic lateral sclerosis (ALS). METHODS: PubMed, EMBASE, OVID, and Web of Science were searched systematically until December 2021 for studies quantitatively investigating the effect of medications on hypertension, hyperlipidemia, and diabetes on the risk of ALS. We conducted a fixed-effects model or random-effects meta-analysis to calculate the summary ORs (odds ratios) and 95%CIs (confidence intervals). RESULTS: Regular intake of angiotensin-converting enzyme inhibitors (ACEIs) (OR: 0.81, 95%CI: 0.74, 0.89), beta-blockers (OR: 0.82, 95%CI: 0.76, 0.90), calcium-channel blockers (CCBs) (OR: 0.85, 95%CI: 0.79, 0.93), or diuretics (OR: 0.87, 95%CI: 0.81, 0.93) was inversely associated with the incidence of ALS. There was no significant association between statin use and risk of ALS (OR: 0.92, 95%CI: 0.83, 1.03). Metformin (OR: 0.83, 95%CI: 0.75, 0.93) and sulfonylureas (OR: 0.79, 95%CI:0.71, 0.89) use could significantly reduce the risk of ALS. CONCLUSION: Regular use of anti-hypertensive drugs and anti-diabetes including ACEIs, beta-blockers, CCBs, diuretics, metformin, and sulfonylureas could protect against the incidence of ALS. No significant association between anti-hyperlipidemia drug use and risk of ALS was revealed. Regular medications for hypertension, hyperlipidemia, and diabetes should be recommended regardless of the diagnosis of ALS.
Authors: Jéssica Paloma Rosa Silva; José Bomfim Santiago Júnior; Elizabete Lima Dos Santos; Fernanda Oliveira de Carvalho; Iandra Maria Pinheiro de França Costa; Deise Maria Furtado de Mendonça Journal: Neurosci Biobehav Rev Date: 2020-01-07 Impact factor: 8.989
Authors: Matthew C Kiernan; Steve Vucic; Benjamin C Cheah; Martin R Turner; Andrew Eisen; Orla Hardiman; James R Burrell; Margaret C Zoing Journal: Lancet Date: 2011-02-04 Impact factor: 79.321
Authors: Jeldican Visser; Renske M van den Berg-Vos; Hessel Franssen; Leonard H van den Berg; John H Wokke; J M Vianney de Jong; Rebecca Holman; Rob J de Haan; Marianne de Visser Journal: Arch Neurol Date: 2007-04
Authors: Jonathan A Knibb; Noa Keren; Anna Kulka; P Nigel Leigh; Sarah Martin; Christopher E Shaw; Miho Tsuda; Ammar Al-Chalabi Journal: J Neurol Neurosurg Psychiatry Date: 2016-07-04 Impact factor: 10.154